This article is more than 5 years old. Information may no longer be current.
Topical NSAID prevents pseudophakic CME in eyes with certain risk factors
Click Here to Manage Email Alerts
CHICAGO — The use of once-daily 0.3% nepafenac after cataract surgery can help prevent pseudophakic cystoid macular edema in eyes with certain risk factors, but did not improve PCME outcomes in eyes without those risk factors, according to a presenter here.
“We are able to show we had a significantly improved PCME outcome with risk factors. This is, in the general ophthalmology practice, about 10% to 30% of patients. However, in 70% to 90% of the patients, it is unlikely that clinical PCME outcomes are improved in those patients without risk factors,” Sean J. McCafferty, MD, said at the American Academy of Ophthalmology meeting.
Sean McCafferty
McCafferty and colleagues conducted a prospective, randomized, double-blind, placebo-controlled study that included 1,000 eyes evenly delegated to the nonsteroidal anti-inflammatory drug or placebo cohort. Clinical PCME was defined as patients who lost two lines of best corrected visual acuity or had visually symptomatic distortion.
McCafferty reported that 308 eyes had risk factors and 692 eyes did not have those factors.
In addition to improving PCME outcomes in eyes with risk factors, McCafferty said the NSAID likely provided additional anti-inflammatory benefits. – by Robert Linnehan
Reference:
McCafferty SJ. Pseudophakic cystoid macular edema prevention and risk factors: Prospective study with once-daily topical nepafenac 0.3% vs. placebo. Presented at: American Academy of Ophthalmology annual meeting; Oct. 14-18, 2016; Chicago, Ill.
Disclosure: McCafferty reported no relevant financial disclosures.